Current position

The Vanguard Group, Inc.’s Arrowhead Pharmaceuticals In (ARWR) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

The Vanguard Group, Inc.Verified through Q4 2025
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares16.04MHighest verified quarter-end share count
Quarters reported8Verified quarters with shares above zero
What happened?

The Vanguard Group, Inc. first reported Arrowhead Pharmaceuticals In in Q2 2016. The reported position was increased and reduced across later filings. The Vanguard Group, Inc. currently reports 15.29M shares. The latest verified filing showed: Sold 4.6% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2025
Sold 4.6% of the position−742.75K shares · 15.29M shares remained
Filing context

Quarter-end price $66.39

Q3 2025
Bought 3.3% more+510.80K shares · 16.04M shares reported after the change
Filing context

Quarter-end price $34.49

Q1 2023
Bought 3.9% more+401.70K shares · 10.69M shares reported after the change
Filing context

Quarter-end price $25.40

Q4 2020
Bought 1.8% more+160.67K shares · 9.28M shares reported after the change
Filing context

Quarter-end price $76.73

Q1 2020
Sold 1.7% of the position−168.98K shares · 9.63M shares remained
Filing context

Quarter-end price $28.77

Q4 2019
Sold 9.7% of the position−1.05M shares · 9.80M shares remained
Filing context

Quarter-end price $63.43

Portfolio importance

How important is Arrowhead Pharmaceuticals In in The Vanguard Group, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q4 2025
Current rank#712of 4329 reported positions
Peak portfolio weight0.0%Q4 2019
Best historical rank#712Q4 2025
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$66.482026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$66.39Q4 2025

Derived from validated reported value and shares where supported.

Latest verified investor filingQ4 2025 · filed 2026-01-29
Open SEC filing ↗

Coverage is bounded to Vanguard’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Vanguard’s complete global assets, fund-by-fund ownership, exact trade dates or execution prices.